Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.44 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910678 | 0.90 | FYN (0.48) | EGFRERBB2ERBB3DUS2 | |
| SCHEMBL2943607 | 0.90 | EGFR (0.52) | EGFRERBB3DUS2 | |
| SCHEMBL9911468 | 0.85 | EGFR (0.71) | EGFRERBB2MAPK1 | |
| SCHEMBL7802729 | 0.84 | EGFR (0.71) | EGFRERBB2ERBB3DUS2 | |
| SCHEMBL9911564 | 0.84 | MKNK1 (0.50) | EGFRERBB2ERBB3DUS2 | |
| SCHEMBL7811790 | 0.82 | EGFR (0.56) | EGFRERBB2MAPK1HTTHIF1A | |
| SCHEMBL9911451 | 0.81 | EGFR (0.55) | EGFRERBB2ERBB3DUS2 | |
| SCHEMBL9911501 | 0.81 | EGFR (0.57) | EGFRERBB2 | |
| SCHEMBL2948798 | 0.80 | EGFR (0.51) | EGFRERBB2ERBB3DUS2 | |
| SCHEMBL7809310 | 0.79 | EGFR (0.59) | EGFRERBB2MAPK1HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB2 170/4885MAPK1 92/4885 |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB2 170/4885MAPK1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.